We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Suppression of thyroid profile during roxadustat treatment in chronic kidney disease patients.
- Authors
Cheng, Yuan; Xiang, Qiong; Cao, Tao; Tang, Fei; Chen, Jia; Qi, Dongli; Hu, Haofei; Song, Haiying; Chang, Zheyi; Ku, Ming; Chen, Xinglin; Chen, Chi; Wan, Qijun
- Abstract
Renal anaemia is a common complication of chronic kidney disease (CKD) and the severity of anaemia increases with the deterioration of renal function [[1]]. Patients who were treated with levothyroxine before roxadustat or EPO treatment were excluded. Patients were included if they underwent at least two serum TSH measurements (before and during roxadustat or EPO treatment), were >=18 years of age and received roxadustat or EPO treatment for at least 4 consecutive weeks. Our objective was to evaluate the effects of roxadustat/erythropoietin (EPO) on thyroid stimulating hormone (TSH) and thyroid hormone levels in CKD patients without primary hypothyroidism.
- Subjects
CHRONIC kidney failure; CHRONICALLY ill; THYROID gland; THYROID hormone receptors; THYROID diseases; HDL cholesterol
- Publication
Nephrology Dialysis Transplantation, 2023, Vol 38, Issue 6, p1567
- ISSN
0931-0509
- Publication type
Article
- DOI
10.1093/ndt/gfad017